The corneal endothelium is a thin monolayer of hexagonal, epithelial-like cells lining the posterior cornea. Corneal endothelial cells (CECs) dynamically regulate corneal hydration through a pump–leak function, in which nutrient-rich aqueous humor leaks through the semipermeable endothelial monolayer into the stroma, and excess fluid is actively transported back out of the stroma via Na
+/K
+-ATPase osmotic pumps.
38,39 CECs require high levels of metabolic activity to sustain osmotic pump activity,
40 rendering them particularly susceptible to chemicals that interfere with mitochondrial respiration or glycolytic metabolic pathways.
41 In contrast to the highly regenerative epithelium, human CECs have limited proliferative capacity in vivo.
42,43 Instead, CECs respond to endothelial lesions by migrating, thinning, and spreading to re-establish adhesions with proximal cells.
44 Despite a steady age-related loss of endothelial cells (∼0.6% per year), corneal transparency is maintained as long as the cell density exceeds 1000 cells/mm
2.
45 Adult human corneas have an average CEC density of ∼2500 cells/mm
2, suggesting that the endothelium has a modest capacity to repair lesions that is diminished over time.
46 Chemical exposures that cause a significant degree of CEC toxicity result in acute edema. If the corneal endothelium heals, then edema will resolve; however, the cornea will be predisposed to the future emergence of endotheliitis when the cumulative effects of acute CEC loss and age-related loss exceed the threshold for decompensation. Clinical endotheliitis emerges when the endothelium can no longer compensate for the stromal swelling pressure. The resulting stromal edema disrupts clarity and visual acuity and elicits secondary keratopathies such as neovascularization, bullous keratopathy, and limbal toxicity, which further compromise corneal function.
47 Currently, endotheliitis can only be treated by corneal transplant surgeries.
48,49 Although there is preliminary evidence that rho-kinase (ROCK) inhibitors may potentiate corneal endothelial wound healing,
50 the precise therapeutic mechanisms and clinical efficacy remain to be convincingly demonstrated. Notably, ROCK inhibitors have been reported to facilitate cell-based regenerative strategies for corneal endothelium, in which CECs are expanded in vitro, without losing their endothelial phenotype, and then injected into the anterior chamber as a cell suspension or implanted as a sheet onto the Desçemet's membrane.
51